Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

6.900 +0.390 (+5.99%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Which stocks are moving before the opening bell on Tuesday? ↗
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
Study Reveals Early Development of Pediatric Brain Tumors in Specialized Nerve Cells
Via Investor Brand Network
AI Can Predict the Recurrence of Brain Tumors in Kids, Study Finds
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
Study Identifies Key Enzyme That Could Be Targeted to Fight Brain Cancers
Via Investor Brand Network
The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035
Via Investor Brand Network
News headline image
Top stock movements in today's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
The market is filled with gapping stocks in Tuesday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
News headline image
Study Uncovers Drivers of Brain Tumor Growth, Could Open New Treatment Approaches
Via Investor Brand Network
News headline image
Pitt Researchers Develop Diagnostic Tool for Profiling Pediatric Brain Cancers
Via Investor Brand Network
News headline image
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position
Via Investor Brand Network
Firefighters Have an Increased Chance of Having Gene Mutations Associated with Brain Cancer, Study Says
Via Investor Brand Network
News headline image
Top movers analysis one hour before the close of the markets on 2025-03-25: top gainers and losers in today's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Nasdaq Gains 50 Points; US New Home Sales Rise In February ↗
 
Via Benzinga
News headline image
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects ↗
CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy to Lomustine in recurrent GBM. 
Via Benzinga
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial
Via Investor Brand Network
News headline image
Which stocks are moving before the opening bell on Tuesday? ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
US Stocks Mixed; Core & Main Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Via ACCESS Newswire
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.